Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Microbial enzymes and intracellular proteins represent a broad and heterogeneous category of therapeutic targets rather than a single molecular entity. This group encompasses a vast array of proteins essential for the survival, replication, and pathogenicity of bacteria, viruses, fungi, and parasites. Examples include DNA polymerases, proteases, ribosomes, and metabolic enzymes like dihydrofolate reductase. In the context of infectious diseases, these targets are exploited by antimicrobial agents to achieve selective toxicity, ideally inhibiting the microbial protein without affecting human orthologs. Because this term describes a functional class across multiple kingdoms of life, it is considered too broad for specific drug-target profiling and typically requires specification of a particular enzyme or organism.
Inhibition of essential microbial metabolic pathways, protein synthesis, or nucleic acid replication.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Microbial enzymes and intracellular proteins.